Scleral spacing procedure and its indications in glaucoma treatment

Article

Dr Soloway discusses a novel approach for treating glaucoma known as the scleral spacing procedure (SSP) using PresView Scleral Implants

One of the reasons surgical control of glaucoma has been advocated by the American Academy of Ophthalmology, with the publication of their preferred practice pattern treatment guidelines since 2003, is because of the non-compliance issues. The penetrating trabeculectomy - with or without the use of anti-metabolites - is used as the 'gold standard' to measure all glaucoma surgical procedures against. The problems of this intraocular filtering procedure have long been known, including hypotony, scarring and failure of the bleb, bleb leakage and infection. Numerous other alternatives are now available or in the pipeline and attempting to ameliorate these issues, but all continue to have the same problems of any penetrating procedure aimed at controlling the outflow of aqueous over the long-term. Each has its own 'Goldilocks' approach, of not enough filtration or too much in an effort to reach just the right amount of filtration.

We have found a novel approach to the treatment of glaucoma known as the scleral spacing procedure (SSP) using PresView Scleral Implants (PSI, Refocus-Group, Dallas, Texas, USA). These implants are being studied as a treatment for presbyopia in an FDA monitored investigational device exemption (IDE) clinical trial currently underway in the US. During the initial phase of that study, it was found that the implants also appeared to have an IOP lowering effect on the normotensive presbyopic emmetropes in whom they were implanted. Although not clinically significant in this group of patients without glaucoma, a statistically significant reduction in IOP of approximately 20% was found in patients with baseline IOP of ?16 mmHg. Our interpretation of these results - and the similarity in age of onset for presbyopia and POAG - led to an interest in conducting a study regarding the use of SSP for early POAG and OHT patients as an alternative to medical and or penetrating surgical treatment. By removing patient compliance issues, side effects of medication usage, risk of hypotony, and variability of penetrating surgery, the SSP may become a first line treatment in glaucoma care.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.